These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11728284)

  • 1. Why lowering blood pressure is not enough: the hypertension syndrome and the clinical context of cardiovascular risk reduction.
    Neutel JM
    Heart Dis; 2000; 2(5):370-4. PubMed ID: 11728284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased vascular compliance/decreased cardiovascular risk: what the studies tell us.
    Frishman WH
    Heart Dis; 2000; 2(5):384-8. PubMed ID: 11728287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic and cardiovascular characteristics of hypertension. Familial aspects.
    Neutel JM; Smith DH
    Cardiol Clin; 1995 Nov; 13(4):539-47. PubMed ID: 8565017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League.
    Lüders S; Schrader J; Berger J; Unger T; Zidek W; Böhm M; Middeke M; Motz W; Lübcke C; Gansz A; Brokamp L; Schmieder RE; Trenkwalder P; Haller H; Dominiak P;
    J Hypertens; 2008 Jul; 26(7):1487-96. PubMed ID: 18551027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New treatment guidelines for a patient with diabetes and hypertension.
    Mogensen CE
    J Hypertens Suppl; 2003 Mar; 21(1):S25-30. PubMed ID: 12769164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypertension as a risk factor syndrome: therapeutic implications.
    Weber MA
    Am J Med; 1993 Apr; 94(4A):24S-31S. PubMed ID: 8488853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome.
    Leenen FH
    Can J Cardiol; 2004 Aug; 20 Suppl B():77B-82B. PubMed ID: 15309209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood pressure-lowering drugs: essential therapy for some patients with normal blood pressure.
    Fuchs FD
    Expert Rev Cardiovasc Ther; 2004 Sep; 2(5):771-5. PubMed ID: 15350178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal medical management of peripheral arterial disease.
    Rice TW; Lumsden AB
    Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood pressure and cardiovascular disease: what remains to be achieved?
    Franklin SS
    J Hypertens Suppl; 2001 Sep; 19(3):S3-8. PubMed ID: 11713848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.
    Kenchaiah S; Davis BR; Braunwald E; Rouleau JL; Dagenais GR; Sussex B; Steingart RM; Brown EJ; Lamas GA; Gordon D; Bernstein V; Pfeffer MA;
    Am Heart J; 2004 Aug; 148(2):356-64. PubMed ID: 15309009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood pressure control and drug therapy in patients with diagnosed hypertension: a survey in Italian general practice.
    Filippi A; Paolini I; Innocenti F; Mazzaglia G; Battaggia A; Brignoli O
    J Hum Hypertens; 2009 Nov; 23(11):758-63. PubMed ID: 19242492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of hypertension in patients with cardiac disease: use of renin-angiotensin blocking agents.
    Prisant LM
    Am J Med; 2008 Aug; 121(8 Suppl):S8-15. PubMed ID: 18638617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on the drug treatment of hypertension in patients with cardiovascular disease.
    White WB
    Am J Med; 2005 Jul; 118(7):695-705. PubMed ID: 15989899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On arterial physiology, pathophysiology of vascular compliance, and cardiovascular disease.
    Glasser SP
    Heart Dis; 2000; 2(5):375-9. PubMed ID: 11728285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease.
    Brugts JJ; Ferrari R; Simoons ML
    Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):345-60. PubMed ID: 19379059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between the metabolic syndrome and the development of hypertension in the Hong Kong Cardiovascular Risk Factor Prevalence Study-2 (CRISPS2).
    Cheung BM; Wat NM; Man YB; Tam S; Cheng CH; Leung GM; Woo J; Janus ED; Lau CP; Lam TH; Lam KS
    Am J Hypertens; 2008 Jan; 21(1):17-22. PubMed ID: 18091739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ESH-ESC guidelines for the management of hypertension.
    Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
    Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.